To Compare the Effect with Vildagliptin (50mg qd, 50mg bid or 100mg qd) to Placebo in Patients with Type 2 Diabetes
Phase 3
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-jRCT2080220283
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 236
Inclusion Criteria
Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both
Inclusion Criteria:
- Diagnosis of type 2 diabetes
- Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels
- Outpatients
Exclusion Criteria
- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- Significant cardiovascular complications
- Significant diabetic complications
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method